Jefferies sees Arbutus (NASDAQ:ABUS) potentially benefitting from vaccines being developed by Moderna (MRNA) and Pfizer (PFE) ...

Engineers have developed a lipid nanoparticle (LNP) that delivers mRNA therapeutic ... the delivery molecules that helped get the mRNA of the COVID vaccine into cells, and their ability to reach ...

Penn Engineers have modified lipid nanoparticles (LNPs)—the revolutionary technology behind the COVID-19 mRNA vaccines—to not ...

The vaccine – developed by researchers at the University of Florida (UF) in the US – is based on mRNA taken from the patient’s tumour that is delivered in a lipid nanoparticle (LNP ...

Long before mRNA vaccines captured global attention during the COVID-19 pandemic, researchers were already exploring their ...

mRNA vaccines offer clear advantages and disadvantages ... “In addition, advances in delivery technologies over current gold-standard LNP approaches to improve immunogenicity and reduce dosing ...

But compared to standard lipid nanoparticles used in mRNA vaccines, the new bubbles—dubbed LNP 55—were 150 times more likely to home in on their target. In two mouse models of pre-eclampsia, a single ...

RNA vaccines have been a long time coming, but were only approved after covid-19 emerged, marking the beginning of a new way ...

2024年10月8日，杜克大学Nicholas S Heaton携手mRNA诺奖得主Drew Weissman在《Nature Communications》杂志上发表题为“Improved influenza vaccine responses ...

Vaccine stocks and EV maker Lucid Technologies (LCID) are among today’s biggest winners today. Vaccine makers, including ...

A 13-year-old girl in Canada became so sick with H5N1, or bird flu, in late 2024 that she had to be put on a ventilator.

The regulatory and manufacturing challenges of the increasingly dynamic and multifaceted landscape of mRNA therapeutics ...